Progress and Promise in the Identification and Management of Interstitial Lung Disease

 

Release Date: July 31, 2018

Last Reviewed: July 16, 2018

Expiration Date: July 31, 2019

Time to Complete Activity:  0.5 hour

*This activity expired for credit on July 31, 2019 and is no longer available for credit
 

 

Assistant Professor
Director of KU ILD & Rare Lung Disease Clinic

Division of Pulmonary and Critical Care Medicine

University of Kansas Health Care System

Kansas City, KS

 

Medical Director, Interstitial Lung Disease Program

Associate Professor of Medicine

Division of Allergy, Pulmonary and Critical Care Medicine

Vanderbilt University Medical Center

Nashville, TN

 

Associate Professor of Medicine and Epidemiology

Division of Pulmonary, Allergy, and Critical Care Medicine

Co-Director, Interstitial Lung Disease Program

Columbia University Medical Center

New York, NY

 

Program Director, Interstitial Lung Disease Program

Assistant in Medicine

Division of Allergy, Pulmonary and Critical Care Medicine

Vanderbilt University Medical Center

Nashville, TN

This activity is provided by Paradigm Medical Communications, LLC.  

 

Target Audience
This activity has been designed to address the educational needs of pulmonologists, radiologists, and pathologists. The activity may also benefit primary care physicians, PAs, nurse practitioners, nurses, pharmacists, fellows, residents, and other allied healthcare providers who care for patients with interstitial lung disease.

 

Interstitial lung diseases (ILDs) are progressive, severely debilitating, and often associated with high mortality. Detecting an ILD—and then differentiating it from the staggering array of diseases that fall under this umbrella—is further challenged by nonspecific, overlapping symptoms, which necessitate rigorous multidisciplinary evaluation to accurately assess patients. Early identification is more worthwhile than ever, given the availability of unprecedented treatment options that can slow the decline of lung function in patients with idiopathic pulmonary fibrosis (IPF). To ensure optimal outcomes, clinicians must become better acquainted with the in-depth, collaborative process necessary to clinch the detection and differentiation of ILDs; novel and emerging options to treat them; and ILD experts and centers that can support such a management scheme.

 

Upon proper completion of this activity, participants should be better able to:

Paradigm Medical Communications, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

 

Paradigm Medical Communications, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PAs may claim a maximum of 0.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
 

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.  Individuals are responsible for checking with the AANPCP for further guidelines.
 

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

 

To receive a CME certificate of participation, you should:

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.

 

There is no fee required for participation in this activity.

This certified CME activity is an interactive infographic designed for you to click, hover, or tap buttons where instructed. 

 

For Desktops (Windows/Mac): Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher

 

For Tablets (iPad/Android/Surface): iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher

 

Technical Support: If you have any technical problems or playback issues email us at contactus@paradigmmc.com.

 

In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.

 

Contracted Speaker: Boehringer Ingelheim Pharmaceuticals, Inc

 

Researcher: Boehringer Ingelheim Pharmaceuticals, Inc; Celgene Corporation; Genentech, Inc.; Novartis Pharmaceuticals Corporation

Advisory Boards: Bellerophon Therapeutics, Genentech, Inc.

Disease State Education: Boehringer Ingelheim Pharmaceuticals, Inc, Genentech, Inc.

 

Retained Consultant: FibroGen, Inc.; Galapagos NV; Global Blood Therapeutics Inc.; Roche; Veracyte, Inc., Sanofi Genzyme

 

Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc

Speaker: Boehringer Ingelheim Pharmaceuticals, Inc

 

Paradigm Medical Communications, LLC, staff members have no financial relationships to disclose.

Independent peer reviewer has no financial relationships to disclose.

 

Resolution of Conflict of Interest
Paradigm Medical Communications, LLC, has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.

 

This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

 

As an ACCME-accredited provider, Paradigm Medical Communications, LLC, activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

 

The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC, accepts no liability for the content referenced in this activity.

 

Paradigm Medical Communications, LLC, is committed to protecting the privacy of those who participate in the activities (herein referred to as “website") located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

 

This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

 

The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC, to continuously improve the learning experience.

 

Paradigm Medical Communications, LLC, does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC, will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC, staff members review individual test results to the extent necessary to record and track participants’ credits.

 

Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.

 

© 2018 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.